Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT
NEW INDICATION OF BIREOCICLIB INCLUDED IN THE 2026 NATIONAL REIMBURSEMENT DRUG LIST

The board of directors (the "**Board**") of Xuanzhu Biopharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the new indication of the Company's independently developed innovative drug, Bireociclib Tablets, in combination with aromatase inhibitors ("**AIs**") for the first-line treatment of patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) ("**HR+/HER2-**") advanced breast cancer, has been included in the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (Year 2026) (the "**2026 NRDL**"). The 2026 NRDL will officially take effect on 1 January 2027. As of the date of this announcement, all three indications of Bireociclib approved in Mainland China have been included in the NRDL.

With the inclusion of the new indication of Bireociclib Tablets in combination with AIs for the first-line treatment of HR+/HER2- advanced breast cancer in the 2026 NRDL, Bireociclib will achieve full medical insurance reimbursement coverage across the first-line, second-line and later-line treatment of HR+/HER2- advanced breast cancer. This is expected to effectively reduce the financial burden of medication on patients and enhance the accessibility of innovative drugs.

The Board believes that the inclusion will further expand the potential patient population benefiting from Bireociclib and help accelerate its hospital access and clinical application, thereby promoting the commercialisation of Bireociclib and further consolidating the Group's competitive advantages in the field of HR+/HER2- advanced breast cancer treatment.

ABOUT BIREOCICLIB

Bireociclib Tablets (trade name: Xuan Yue Ning), as the first CDK2/4/6 inhibitor approved in China, possess a unique multi-target synergistic mechanism of action, offering advantages including potent inhibition of tumor cell proliferation and significant reduction of the hematological toxicity commonly associated with traditional CDK4/6 inhibitors. Currently, Bireociclib Tablets have been approved by the National Medical Products Administration (NMPA) for three indications, namely: (i) in combination with AIs for the initial endocrine treatment of adult patients with HR+/HER2- locally advanced or metastatic breast cancer; (ii) in combination with fulvestrant for the treatment of adult patients with HR+/HER2- locally advanced or metastatic breast cancer who have experienced disease progression following prior endocrine therapy; and (iii) as monotherapy for the treatment of adult patients with HR+/HER2- advanced or metastatic breast cancer who have experienced disease progression following two or more prior endocrine therapies and one chemotherapy regimen during the metastatic stage. As at the date of this announcement, all three indications have been included in the NRDL.

This announcement is a voluntary announcement made by the Company for the purpose of keeping its shareholders and potential investors informed of the Group's latest business developments and does not contain any advertisement or intention regarding the use of any drugs, surgical equipment, treatments, or oral products.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, 15 November 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; (iii) Ms. Yue Xin as employee representative Director; and (iv) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.